- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 29, 2024
Deals
Deals Report: GSK is latest pharma to draw on Flagship portfolio
Plus: Day One’s ex-U.S. deal with Ipsen; Novartis taps Dren Bio’s oncology platform; BI buys Avalon-backed Nerio; and Collegium’s ADHD takeout
BioCentury | Oct 6, 2023
Discovery & Translation
An AbbVie-Calico cancer therapy; plus Moderna’s monkeypox vaccine and more
BioCentury’s roundup of translational innovations
BioCentury | May 13, 2022
Data Byte
Distillery spotlight on Italian innovation
Opportunities include compounds and targets for cancer, neurology and musculoskeletal diseases, and discoveries from company founders
BioCentury | Jun 26, 2019
Distillery Therapeutics
Inhibiting PTP-1B to improve islet graft outcomes for Type I diabetes
BioCentury | Jul 13, 2018
Clinical News
Cold Harbor JV developing copper chelator for Wilson's disease
BioCentury | Aug 11, 2016
Product R&D
SHP-2 sets sail
How NIBR made the first drug-like SHP-2 inhibitor
BioCentury | Jan 18, 2016
Strategy
Warp's independence day
Why Warp, Sanofi reworked their build-to-buy partnership into a licensing deal
Items per page:
1 - 10 of 87